Background:
Recently an important role for synovial pathology in the initiation and progression of knee osteoarthritis (OA) has been emphasised. Our previous cross-sectional study showed that synovial changes on US associated with knee pain (KP), but the association was confounded by radiographic severity [1] Objectives: To examine whether these synovial changes associate with KP changes over 1 year. Methods: 220 participants with early KP (<3yrs duration) identified from the Knee Pain and Related Health in the Community (KPIC, n=9514) survey in Nottingham, UK formed the cohort for this study. All participants had bilateral US and radiographic examination at baseline, and US was repeated after 1 year. KP was defined as pain in or around the knee on most days for at least a month, and KP severity was measured using a numerical rating scale (NRS 0-10). Change in KP severity was defined according to a Patient Global Impression of Change. Synovial changes (effusion, hypertrophy and Power Doppler (PD) signal) were measured by two observers (inter-observer concordance correlation was 0.8 (0.6 to 0.9) for effusion and 0.7 (0.5 to 0.9) for synovial hypertrophy). Standardised radiographs (semi-flexed weight-bearing and flexed skyline views) were scored using the Nottingham Line Drawing Atlas (NLDA). Radiographic OA was defined as definite joint space narrowing (grade 2) plus definite osteophyte (grade 2) in any compartment. An absolute change in effusion/synovial thickness/pain scores was calculated by subtracting the baseline measure from the follow-up measure within individuals. A correlation analysis was used to examine the association between changes in pain and changes in US values. Potential baseline predictors for KP worsening were examined using multivariate logistic regression analysis. Results: Of 220 participants in this cohort, 165 (75%) had US measurements at baseline and follow-up (mean age 61yrs; 61% women; 24% ROA). The mean NRS score decreased from 4.44 to 3.01 mm. The mean depth of the effusion and synovial hypertrophy changed from 4.01 mm to 5.37 mm, and from 1.82 to 2.45 mm, respectively. There was no correlation between changes in pain on NRS and changes in US-detected synovial change (Figure 1) . At 1 year follow-up, 58% reported that their KP had improved from baseline, 16% reported worsening, and 27% reported no change in KP. After adjustment for age, gender and BMI baseline US features did not predict worsening pain, whereas ROA did (OR=4.06 95% CI 1.55 to 10.61).
Conclusions:
This cohort study showed that US-detected knee "synovitis" was not a predictor of change in OA symptoms, whereas baseline radiographic OA severity was. It suggests that synovial changes detected by US might reflect aspects of OA pathology discrete from mechanisms driving OA pain change.
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[1] Sarmanova A, et al. Arthritis Rheumatol. 2016; 68 (suppl 10) . http://acrabstracts.org/abstract/synovial-changes-detected-by-ultrasoundand-its-association-with-knee-pain-a-population-based-case-control-study/. Acknowledgements: Arthritis Research UK (Grant Refs: 20777 and 20194) Background: Rheumatic diseases are the leading cause of permanent disability. In our country are the fourth cause of consultation in health institutions. The COPCORD model constitutes an effective tool in the determination of the prevalence of diseases. Globally, this model has been carried out in Asia, Europe and in some countries of Latin America. In Colombia the epidemiology of rheumatic diseases is not known globally; this would be the first national study that uses the data collection questionnaire using the COPCORD instrument Objectives: To estimate the prevalence of rheumatic disease and related factors in a Colombian population over 18 years of age in six Colombian cities Methods: A Cross-sectional analytical study was designed in people older than 18 years. A probabilistic stratified sampling method using three stages. The first stage of sampling was the selection of cartographic sectors in each city. The second stage of sampling was the blocks of each sector. The third stage of sampling was the homes of each block. All household members were surveyed. The sample size was calculated to be 6,528 people (2336 from Bogotá, 1220 from Medellín and Cali each, 746 from Barranquilla, 503 from Bucaramanga and Cúcuta each). The COPCORD questionnaire adapted for Colombia, was applied in the first stage by standardized interviewers. Positive cases were reviewed at home by a first year rheumatology fellow. To assess whether it is a rheumatic disease; the positive cases for a probable rheumatic disease were reviewed by a second year rheumatology fellow and reviewed again with laboratory and image studies by a certified rheumatologist to establish the definitive diagnosis Results: 3,146 men and 3,547 women were included. Pain in the last 7 days not associated with trauma was reported in 3,213 (48%) participants. The most frequent sites were knees (right 31%, left 29%), hands (right 25%, left 24%), lumbar spine (18%) and shoulders (right 16%, left 14%). Table 1 Background: Infection is a complication of biologic therapy in RA. Objectives: To describe the incidence and pattern of serious infection within the British Society for Rheumatology Biologics Register (BSRBR-RA) by drug. Methods: The BSRBR-RA is a prospective observational study designed to evaluate the safety of biologics. Adverse events are coded using MedDRA defintitions. This analysis included patients with RA starting a biologic. They were considered at risk from their start date until 3 half-lives after stopping their biologic, death, first serious infection, or completion of three years of therapy, whichever came first. Event rates were compared across biologics using Cox proportional hazards with adjustment for age, gender, disease severity and duration, smoking, seropositivity, polypharmacy and baseline steroid usage. Results: 19,282 patients were included in the analysis with combined follow-up time of 46,771 years. At baseline the mean age was 57 years, 76% female, mean disease duration 12.3 years and mean DAS28 6.1. 22% were current smokers and 64% had a positive rheumatoid factor. The incidence of serious infection for each biologic and hazard ratios for serious infections including by subclass are tabulated. A sensitivity analysis limiting to 1st biologic exposure only did not significantly alter the estimates. A second sensitivity analysis limiting to new starters from 2010 found certolizumab still had a lower point estimate but findings were no longer significant (HR 0.79, ).
Conclusions:
Although the incidence of serious infection was lowest with certolizumab it is difficult to draw strong conclusions about comparative safety from observational studies due to channelling bias and unmeasured confounding. Rituximab and tocilizumab both had higher unadjusted rates of infection but in the adjusted model the rate was no different suggesting that patient factors as opposed to the drug itself were responsible for the observed difference. Background: Anti-TNF alpha treatment may improve endothelial function and mechanical properties of large artery stiffness in patients with inflammatory rheumatic diseases, however studies remain controversial. Objectives: To study the effect of TNF alpha blockage with adalimumab for 24 weeks on brachial endothelial function and sub-clinical markers of atherosclerosis in patients with inflammatory rheumatic diseases. Methods: A total of 26 patients (14 males, 12 females; mean age, 47±11 years) with inflammatory rheumatic diseases (16, rheumatoid arthritis; 9, ankylosing spondylitis, 1, psoriasic rheumatism), resistant to disease-modifying antirheumatic drugs, were studied before the first infusion of adalimumab and again after 24 weeks of treatment. Endothelial function was assessed by measuring flow mediated dilatation using an ultrasound Doppler technique on the brachial artery. Other markers of sub clinical atherosclerosis were assessed by arterial stiffness via aortic pulse wave velocity, augmentation index and central blood pressure, and carotid intima-media thickness. Data for body mass index, disease activity using DAS-PCR and BASDAI, C-reactive protein, fasting glycaemia, and lipid profile were collected before treatment and after 24 weeks. Results: 24 weeks of adalimumab therapy resulted in a reduction of disease activity score and serum levels of C-reactive protein. No significant differences were found in body mass index, total cholesterol, triglycerides and fasting glycaemia. Brachial blood pressure and heart rate remained similar, as well as carotid intima-media thickness. After 24 weeks of treatment with adalimumab, flow mediated dilatation improved significantly; central systolic and diastolic blood pressure decreased significantly; however central pulse pressure, augmentation index and aortic pulse wave velocity remained unchanged. 
